Related Experiment Videos
Lonidamine in primary malignant brain tumors. Preliminary report
Oncology
|January 1, 1984
Summary
Lonidamine showed potential therapeutic activity in malignant glioma patients, with 4 of 16 experiencing benefits. Common side effects like myalgia and nausea were generally manageable during this multicenter drug study.
Area of Science:
- Neuro-oncology
- Clinical Pharmacology
Background:
- Malignant gliomas represent a significant challenge in neuro-oncology.
- Lonidamine is an investigational drug with potential anti-cancer properties.
Purpose of the Study:
- To evaluate the therapeutic activity and side effects of Lonidamine in patients with malignant gliomas.
Main Methods:
- A multicenter study involving 16 patients with malignant gliomas.
- Regular assessments included general and neurological examinations, electroencephalography, electroneuromyography, and CT scans.
Main Results:
- Four out of 16 patients (25%) showed an indication of therapeutic activity.
- The most frequent side effects were myalgia, nausea, and vomiting, which typically subsided during treatment.
Conclusions:
- Lonidamine demonstrated some therapeutic potential in malignant glioma treatment.
- Further investigation is warranted to confirm efficacy and optimize management of side effects.